KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Goodwill & Intangibles (2022 - 2025)

Rigel Pharmaceuticals has reported Goodwill & Intangibles over the past 4 years, most recently at $24.7 million for Q4 2025.

  • Quarterly results put Goodwill & Intangibles at $24.7 million for Q4 2025, down 8.68% from a year ago — trailing twelve months through Dec 2025 was $24.7 million (down 8.68% YoY), and the annual figure for FY2025 was $24.7 million, down 8.68%.
  • Goodwill & Intangibles for Q4 2025 was $24.7 million at Rigel Pharmaceuticals, down from $25.3 million in the prior quarter.
  • Over the last five years, Goodwill & Intangibles for RIGL hit a ceiling of $28.9 million in Q1 2024 and a floor of $13.9 million in Q4 2023.
  • Median Goodwill & Intangibles over the past 4 years was $25.3 million (2025), compared with a mean of $22.0 million.
  • Biggest five-year swings in Goodwill & Intangibles: surged 96.6% in 2024 and later fell 8.68% in 2025.
  • Rigel Pharmaceuticals' Goodwill & Intangibles stood at $15.0 million in 2022, then decreased by 7.48% to $13.9 million in 2023, then skyrocketed by 95.27% to $27.1 million in 2024, then fell by 8.68% to $24.7 million in 2025.
  • The last three reported values for Goodwill & Intangibles were $24.7 million (Q4 2025), $25.3 million (Q3 2025), and $25.9 million (Q2 2025) per Business Quant data.